Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effectsNew analyses showed patients...
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat...
Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy &...
TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of up to 89.2% at 24...
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage...
Horsewood 7-Herb Formula: Tongkat Ali 100:1, Horny Goat Weed, Saw Palmetto, Wild Yam, Nettle, Sarsaparilla, Boron Ingredients and GuaranteeLargo, FL,...
Hartwig to adopt Ultima Genomics' UG200 sequencing system to accelerate implementation of whole-genome-based clinical genomics workflows on Solaris 2.0 technologyHartwig...
Investment to Accelerate Expansion Into New Specialties and MarketsKANSAS CITY, Mo., June 12, 2026 /PRNewswire/ -- Aton Health ("Aton" or...
Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control...
Data from the RALLY-MF trial of DISC-0974 in patients with myelofibrosis (MF) and anemia demonstrate meaningful, durable overall anemia responses...
Company to be Renamed NOMAD Power Solutions • First-to-Market with the Mobile, Utility-Grade 1 MW BESS • Addressing a Multi-Hundred-Billion-Dollar...
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective...
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an updated objective response rate (CR+CRh+PR+CI) of...
PALO ALTO, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative...
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain...
Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2...
Oral presentation at JDA features new data from the KT-621 Phase 1 study in healthy Japanese adults, with safety and...
— Growing body of ORLADEYO® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization...
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile...
COPENHAGEN, Denmark, June 12, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its...